A Phase IV, Randomized, Open-Label, Comparative, Multicenter Study to Assess the Safety and Efficiancy of Induction Agents Alemtuzumab (Campath 1H), Basiliximab (Simulect) or Rabbit Anti-Thymocyte Globulin (Thymoglobulin) in Combination with Tacrolimus